

**SUPPLEMENTARY MATERIAL**

*Table S1. Patient characteristics according to cluster*

Variable	Cluster 1 (n=54)	Cluster 2 (n=83)	p
Physical activity, n (%)	30 (56.60)	43 (53.09)	0.689 <sup>†</sup>
<b>Current mode of administration</b>			
Oral, n (%)	9 (16.67)	21 (25.30)	<b>0.008*<sup>†</sup></b>
Subcutaneous, n (%)	32 (59.26)	57 (68.67)	
Intravenous, n (%)	13 (24.07)	5 (6.02)	
Time since diagnosis, mean (SD)	13.70 (10.85)	14.58 (12.40)	0.9368 <sup>‡</sup>
Time in current treatment, mean (SD)	6.03 (6.15)	6.32 (8.77)	0.7320 <sup>‡</sup>
HAQ score, mean (SD)	1.14 (0.64)	1.22 (0.70)	0.4559 <sup>‡</sup>
<b>Income, n (%)</b>			
< 500€	4 (7.41)	8 (9.64)	0.644 <sup>‡</sup>
500€ to 999€	8 (14.81)	20 (24.10)	
1000€ to 1499€	18 (33.33)	18 (21.69)	
1500€ to 1999€	12 (22.22)	16 (19.28)	
2000€ to 2500€	4 (7.41)	7 (8.43)	
>2500€	0 (0.00)	2 (2.41)	
Unknown/ not answered	8 (14.81)	12 (14.46)	

<sup>†</sup> Pearson's chi-squared test; <sup>‡</sup> Mann–Whitney U test; <sup>±</sup> Fisher's exact test

*Figure S1. Utilities values according to the patients' current treatment route of administration*

